key: cord-0926213-jrwybas0
authors: Blanchard, Ana C.; Waters, Valerie J.
title: Microbiology of Cystic Fibrosis Airway Disease
date: 2019-12-30
journal: Semin Respir Crit Care Med
DOI: 10.1055/s-0039-1698464
sha: 02a90accd4156873258e06ee9d053aa1d01a4c78
doc_id: 926213
cord_uid: jrwybas0

Although survival of individuals with cystic fibrosis (CF) has been continuously improving for the past 40 years, respiratory failure secondary to recurrent pulmonary infections remains the leading cause of mortality in this patient population. Certain pathogens such as Pseudomonas aeruginosa , methicillin-resistant Staphylococcus aureus , and species of the Burkholderia cepacia complex continue to be associated with poorer clinical outcomes including accelerated lung function decline and increased mortality. In addition, other organisms such as anaerobes, viruses, and fungi are increasingly recognized as potential contributors to disease progression. Culture-independent molecular methods are also being used for diagnostic purposes and to examine the interaction of microorganisms in the CF airway. Given the importance of CF airway infections, ongoing initiatives to promote understanding of the epidemiology, clinical course, and treatment options for these infections are needed.

S. aureus include the leukocytolytic toxin Panton-Valentine leukocidin, which has been associated with necrotizing lung infections. 8 In addition, small colony variants 9,10 and biofilm formation 11,12 may contribute to increased antimicrobial resistance and accelerate lung disease. Although the pathogenicity of methicillin-sensitive S. aureus (MSSA) has been questioned, coinfection with other pathogens such as P. aeruginosa may be associated with worsened clinical outcomes including more severe lung disease. 13 Methicillin-resistant S. aureus (MRSA) infection tends to occur more commonly in young adults 6 rather than in children. Methicillin resistance is due to the presence of an altered penicillin binding protein, which is encoded by the mecA gene belonging to the Staphylococcal Cassette Chromosome (SCC). 14 There have been at least 12 types of SCCmec elements described to date. 15, 16 The epidemiology of MRSA is SCCmec type-specific, with hospital-associated MRSA (HA-MRSA) strains being more often SCCmec type I, II, and III, whereas community-associated MRSA (CA-MRSA) strains tend to carry SCCmec type IV or V. 17 Additionally, mecA-negative MRSA (also known as borderline oxacillin-resistant S. aureus or BORSA) is described in CF with βÀlactam resistance through various potential mechanisms, including (1) hyper βÀlactamase enzyme production, 18 (2) plasmid-mediated, inducible methicillinase, 19 or (3) modification of the penicillin-binding protein genes. 20 Initial epidemiological studies in children with CF demonstrated that about two-thirds of MRSA infections were HA-MRSA (SCCmec II strains) and one-third CA-MRSA (SCCmec IV strains) 21 ; however, SCCmec IV strains have been increasing in recent years. 22 The prevalence of MRSA-positive cultures has increased about threefold between 2002 and 2017 in individuals with CF living in the United States. 6 Chronic MRSA infection is of particular significance. It has been associated with several negative clinical outcomes, including accelerated decline in lung function, increased hospitalization, and earlier mortality in patients with CF. Ren et al noted significantly lower lung function in MRSA-infected individuals with CF compared with those with predominant MSSA-positive respiratory tract cultures. 23 Individuals with CF who are MRSA positive have a higher rate of hospitalization and increased use of oral, inhaled, and intravenous antibiotics, compared with MRSA-negative patients. 23 Furthermore, Dasenbrook et al reported that the rate of lung function decline was greater in patients with MRSA compared with MRSAnegative patients in patients aged 8 to 21 years (MRSA-positive patients had a forced expiratory volume in 1 second [FEV 1 ] decline of 2.06% predicted/year compared with 1.44% predicted/year in those without MRSA; difference-0.62% predicted/year, 95% confidence interval [CI]: À 0.70 to À 0.54; p ¼ 0.001). 24 In summary, although both MSSA and MRSA are common pathogens in the CF airways, MRSA in particular is associated with detrimental outcomes in patients with CF.

Pseudomonas aeruginosa is an important gram-negative pathogen in patients with CF. It is a non-lactose fermenter commonly found in freshwater, which grows at an optimal temperature for growth of 42°C. 25 Pseudomonas aeruginosa has several virulence factors associated with infection of the host, including flagella which makes it a motile organism, as well as pili which facilitate attachment to epithelial cells in the respiratory tract. 26,27 Pseudomonas aeruginosa expresses three main exopolysaccharides: alginate, Pel, and Psl, which are important in the establishment and maintenance of a biofilm structure. 28 It grows mainly as an aerobe but can also survive under anaerobic conditions. Pseudomonas aeruginosa is intrinsically resistant to some β-lactam antibiotics and can acquire antimicrobial resistance via either chromosomal mutation or horizontal gene transfer. 29 As per the CF Foundation Patient Registry Annual Report, the percentage of individuals with a positive culture for P. aeruginosa has declined over time, with the largest decrease observed among individuals younger than 18 years (47.0 percent had a positive culture in 1997 compared with 27.5 percent in 2017). 6 The decrease in P. aeruginosa infection prevalence may be due to early antibiotic eradication treatment of incident infections. In 2017, 44.6% of individuals with CF in the United States. were culture positive for P. aeruginosa. 6 Pseudomonas aeruginosa is often initially acquired from environmental sources. Once the bacteria establish themselves in the CF airways, they undergo adaptive changes such as decreasing motility by downregulating flagellum expression. In addition to downregulating of other virulence factors, 30-33 P. aeruginosa will also overproduce exopolysaccharides such as alginate which confers mucoidy status. 33 Chronic infection, which is often monoclonal before undergoing adaptive diversification of clonal variants, has been associated with accelerated lung function decline and earlier mortality. 34 To prevent these poor outcomes, initial and new-onset P. aeruginosa infections are usually aggressively treated in an attempt to eradicate the organism from the airways. 35-37 However, eradication failure remains a problem in this patient population 38 ; chronic phenotype of the isolate such as mucoid status is a risk factors for eradication failure. 39

The Bcc includes over 20 species of nonfermenting gramnegative bacilli, which can be acquired from the environment or transmitted from person to person. 40 Burkholderia species grow under aerobic conditions. This organism is frequently found in the environment, especially soil and potted plants. 41 It is considered to be a highly virulent organism, with factors such as pili facilitating epithelial cell attachment, extracellular proteases resulting in tissue damage, quorum sensing genes facilitating biofilm formation, and a type III secretion system promoting cellular invasion. 42-46 As previously mentioned, Bcc species are intrinsically resistant to several different antimicrobial classes including aminoglycosides due to efflux pumps and β-lactams via inducible chromosomally encoded β-lactamases. 47, 48 The epidemiology of Bcc infections in CF has been extensively examined given the potential for transmission between patients. 49, 50 In 2017, 2.4 percent of individuals with CF in the CF Foundation Patient Registry Annual Report were culture positive for Bcc. 6 In early epidemiological studies, Burkholderia cenocepacia was initially described as the most common Bcc organism in individuals with CF 42,51 and this species has been linked to several epidemic strains worldwide. [52] [53] [54] [55] [56] In particular, the B. cenocepacia ET-12 strain (ET-12Bc) has caused one of the largest epidemics in CF individuals in Canada and the United Kingdom 55 since the 1980s and has been associated with very poor clinical outcomes. The epidemiology of Bcc infections in CF has changed over the last several decades, however, as Burkholderia multivorans is becoming more common than B. cenocepacia. [57] [58] [59] This is thought to be due to implementation and reinforcement of infection control and prevention measures lowering B. cenocepacia 60 acquisition rates, whereas B. multivorans may be more often acquired from the environment. Burkholderia gladioli is a closely related species that is the third most common Burkholderia species isolated in CF, but it is not part of the Bcc.

Burkholderia cenocepacia is of particular importance in CF because it has been associated with poor clinical outcomes including accelerated lung function decline 61 as well as increased mortality both before and after lung transplantation. 62, 63 In addition, B. cenocepacia, 42,64 as well as other species such as B. multivorans, 65 has been linked to cepacia syndrome, a clinical entity characterized by necrotizing pneumonia and sepsis with near-total fatality rates. Therefore, infection with Bcc species remains an important concern in the CF population due to the significant associated morbidity and mortality.

Stenotrophomonas species are gram-negative rods and obligate aerobes. They are nonfermenting, oxidase-negative organisms that can be found in water sources in the environment. Although four species of Stenotrophomonas exist, S. maltophilia is the most common one identified in human hosts. Stenotrophomonas maltophilia virulence factors include extracellular enzymes (such as alkaline serine proteases), outer membrane lipopolysaccharides, 66 and the ability to form biofilms. 67, 68 Antimicrobial resistance may occur due to the presence of multidrug efflux pumps, β-lactamases, aminoglycoside-modifying enzymes, and reduced outer membrane permeability. 69 The prevalence of S. maltophilia has been shown to vary from 12% to as high as 30% in CF populations. [70] [71] [72] [73] Previously identified risk factors for acquisition include antibiotic use, 74 in particular following the use of antipseudomonal agents. 75, 76 Initial infection is thought to be due to acquisition from environmental sources rather than person-to-person transmission.

Previous studies have described that individuals with CF who are infected with S. maltophilia infection tend to be older and have lower baseline lung function compared with patients without S. maltophilia. However, in these studies, S. maltophilia-positive individuals did not have more rapidly declining percent predicted FEV 1 (ppFEV 1 ) or decreased 3year survival. 77, 78 However, chronic S. maltophilia infection (defined as two or more positive cultures in the year prior) has been described as a significant risk factor for pulmonary exacerbations treated with intravenous antibiotics 79 ; it is not, however, associated with a higher risk of failing to recover baseline lung function following an exacerbation event. In addition, registry-based studies have shown that patients with chronic S. maltophilia have a three times higher risk of death or lung transplantation compared with those without S. maltophilia infection. 80, 81 Achromobacter Species

Achromobacter species are gram-negative, catalase-positive, oxidase-positive, nonsporulating rods. Up to 23 species are now known within the Achromobacter genus to date. Achromobacter species tend to grow under aerobic, nonfermentative conditions and at an optimal temperature of 25 to 37°C. They are environmental organisms, commonly found in soil and water. Achromobacter species are motile due to the presence of flagella, and can exhibit binding factors to mucin, collagen, and fibronectin, thereby facilitating initial attachment and invasion of the respiratory tract. 82, 83 Biofilm formation as well as intrinsic resistance to several classes of antimicrobials through the expression of efflux pumps, βlactamases, and aminoglycoside-modifying enzymes [84] [85] [86] is also expressed by this group of pathogens.

Achromobacter xylosoxidans is the most common Achromobacter species identified in individuals with CF, accounting for 42% of Achromobacter respiratory tract infections. 87 Prevalence of Achromobacter infections varies greatly and has been reported between 3 and 30%. 72, 73, 88, 89 Acquisition is thought to occur mostly from the environment, although patient-topatient transmission has been previously described. [89] [90] [91] [92] Published data regarding the risk factors for initial infection and clinical impact of Achromobacter infection are limited and include studies with small sample sizes. Risk factors for chronic infection include older age and chronic P. aeruginosa infection. 88, 93 Of note, patients with chronic Achromobacter infection had lower lung function and more pulmonary exacerbations than age, gender, and P. aeruginosa matched controls in one of the main observational studies assessing clinical outcomes in patients with Achromobacter infection. 88 In a large epidemiologic study using the Toronto CF Database, chronic Achromobacter infection (defined as two or more positive cultures in the previous 12 months) was associated with a twofold increase in the risk of death or lung transplantation compared with patients with no history of Achromobacter infection. 94 Currently, no consensus data exist on optimal treatment strategies for initial acquisition, treatment during pulmonary exacerbation, or for chronic suppression of Achromobacter infections.

Anaerobes are a group of gram-positive and gram-negative organisms which require reduced oxygen for survival. 95 They are commonly found in various mucosal surfaces of the human body including the upper airways, the gastrointestinal tract, and the female genital tract. They have been associated with invasive suppurative infections of the brain, sinuses, lung, liver, and blood vessels. 25 Capsular polysaccharide, hemolysins, proteases, and lipopolysaccharides are virulence factors associated with pathogenic anaerobes. 96 Due to the technical difficulties of isolating and identifying anaerobes in culture-dependent methods, the prevalence of anaerobic infections in patients with CF is not well known. Recently, culture-independent methods have helped identify that anaerobic bacteria are found in abundant quantities in sputum and bronchoalveolar lavage fluid of individuals with CF, with a density estimated between 10 4 and 9 Â 10 7 colony forming unit (CFU)/mL of sputum. 97-100 Some of the main anaerobic bacteria found in the CF airways include Prevotella, Veillonella, Fusobacterium, Propionibacterium, and Actinomyces. 99 However, the role of anaerobes in CF lung disease remains controversial. In recent years, studies have described the association between the detection of anaerobes and diminished clinical response to systemic antimicrobials with lung function decline. 99,101-105 One of the major limitations in the study of anaerobes in CF lung disease is the risk of contamination of lower airway samples by oropharyngeal secretions during collection, 101,106,107 although recent studies have tried to address this concern. Anaerobes may interact with other organisms present in the CF airways, increasing the virulence of P. aeruginosa and transferring extended-spectrum β-lactamases to P. aeruginosa for example. 108, 109 In contrast, the potential beneficial role of anaerobes has also been described in studies using both culture-dependent and culture-independent methods. Patients exposed to antimicrobial therapy may experience a decrease in the relative abundance of anaerobes, with subsequent increased inflammation and decreased lung function. Therefore, reducing microbial community diversity with regard to anaerobes may be playing a role in CF lung disease progression. [110] [111] [112] [113] [114] [115] 

The role of viruses in CF airway disease has increasingly been recognized in recent years, due to ongoing advances in molecular detection, using methods such as polymerase chain reaction. 25 These molecular assays allow for rapid, highly sensitive and relatively cost-effective identification of viruses in the respiratory tract. 116 Viral culture and serology used to be the main methods of detection in the past, but these techniques were limited due to high cost, labor intensity, and lack of sensitivity. 117 The overall prevalence of viral infections during pulmonary exacerbations in individuals with CF is estimated to be between 13 and 60%. 118, 119 However, viral infections may be underreported due to infrequent use of viral swabs and the limited number of respiratory viruses detected in a given assay. The most commonly identified viruses in CF patients are respiratory syncytial virus (RSV), human rhinovirus, influenza types A and B, and parainfluenza virus, 120-122 although many other viruses including human metapneumovirus, picornavirus, coronavirus, and coxsackie/echovirus have also been described. 120, 121, [123] [124] [125] Viral infections are detected more frequently in children than in adults with CF. 126 In addition, children with CF are more likely to experience significant morbidity associated with viral infections compared with children without CF. 117, 123, 127, 128 The increased severity of viral infections in individuals with CF compared with non-CF populations has been linked to reduced innate antiviral response, whereby CF individuals may not mount a sufficient interferon response or adequately express certain interferonstimulated genes, as compared with non-CF controls. 129 Viral infections increase the risk of pulmonary exacerbations in both children and adults with CF, 124,130 as well as increased inflammatory markers, leading to longer duration of intravenous antibiotic therapy and greater drops in lung function. 131, 132 RSV is of particular importance in CF, as it is frequently encountered in both children and adults with CF and can result in severe symptoms. Symptoms may include rhinosinusitis, cough, fever, and acute otitis media; RSV infection can also progress to lower airway disease with bronchiolitis, pneumonia, and exacerbation of chronic airway disease. 133 Recent studies have highlighted that children with CF have increased RSV-related admissions to hospital compared with healthy children. 134 In infants who have CF disease, RSV is associated with significant respiratory morbidity. 135 Increased rates of pulmonary exacerbations, longer stay in hospital as well as prolonged lower airway disease in the 2 years following the initial respiratory infection have been described in these patients. 135 Similarly, influenza virus infection has also been associated with significant morbidity in children with CF, with studies describing an increased risk of admission to hospital for pulmonary exacerbations associated with influenza infection compared with those without. 136, 137 A potential mechanism for these worsened clinical outcomes in individuals with CF who contract respiratory viral infections may be due to the interaction of viruses with bacterial species in the airways and a subsequent change in microbial community composition. Viral infections have been linked to both new acquisition of P. aeruginosa in previously culture-negative patients 138 and conversion from intermittent to chronic P. aeruginosa infection in patients with CF. 117,120,138,139 RSV infection has also been linked to increased P. aeruginosa biofilm formation, through dysregulation of the iron homeostasis in the CF airway epithelium. 140 Similarly, a study has previously shown that identification of both rhinovirus and S. aureus is among the most frequent viral/bacterial coinfection in children. 141 In summary, viral infections are an important component of the CF airway microbial community and contribute to CF lung disease.

Several different yeasts and filamentous fungi can be recovered from the respiratory tract secretions of CF patients. 142 Direct microscopic examination of specimens using fungal stains can reveal yeast cells, pseudohyphae, or hyphae and several media can be used to improve the recovery of fungi from clinical specimens. 95 Fungal growth can take as long as 4 weeks depending on the species. Identification of fungal isolates can be done using microscopic examination, biochemical testing, DNA sequence analysis, or matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. 143 The most common filamentous fungi recovered from CF airways are Aspergillus species with prevalence rates up to Seminars in Respiratory and Critical Care Medicine Vol. 40 No. 6/2019 78%. 144 Often, the recovery of Aspergillus species in CF sputum represents asymptomatic colonization but can represent allergic bronchopulmonary aspergillosis (ABPA). ABPA is characterized by asthma-like symptoms, a positive Aspergillus skin test and an elevated serum IgE. 145 Episodes of ABPA can lead to decline in pulmonary function and are typically treated with systemic steroids. 146, 147 Occasionally, Aspergillus can cause a bronchitis associated with increased pulmonary inflammation. In a study of over 200 children with CF, chronic Aspergillus fumigatus infection was found to be an independent risk factor for pulmonary exacerbation treated with intravenous antibiotics. 148 Although patients with persistent A. fumigatus infection had lower ppFEV 1 during the course of the study compared with those uninfected, there was a significant interaction between A. fumigatus and P. aeruginosa on lung function. Interventional studies of itraconazole treatment of CF patients chronically infected with Aspergillus species did not demonstrate any benefit in terms of lung function or occurrence of pulmonary exacerbation compared with placebo-treated patients. 149 Invasive pulmonary aspergillosis occurs rarely in immunocompetent individuals with CF pretransplant. 150 Scedosporium species are saprophytic filamentous fungi that are much less commonly found in CF patients but can also cause serious invasive disease in immunocompromised conditions. 151 Scedosporiosis infections can involve the lung, bone, eyes, blood vessels, and central nervous system. 152 Exophiala (Wangiella) dermatitidis can also be recovered from CF respiratory specimens. 153 It grows as a black yeast at 37°C and as a filamentous fungus at room temperature. Anecdotal reports describe clinical decline in CF patients who harbor E. dermatitidis in their sputum. 154 Finally, Candida species are the most frequently isolated yeast from CF airways. Its prevalence ranges as high as 80%, which is not surprising given that it is a normal colonizer of the oropharynx. 144 Although studies have suggested that chronic infection with Candida spp. is associated with worse clinical outcomes, these investigations have not controlled for potential contamination of expectorated sputum samples by Candida species present in the oral cavity. 155 

With the advent of culture-independent molecular methods of microbial detection, our understanding of microbial diversity and the interactions of microbial communities in the CF airways has significantly expanded. 102 These newer techniques not only allow the identification of microorganisms, but also the estimation of relative abundances of microbial communities in the CF airways. Methods such as 16S ribosomal ribonucleic acid (rRNA) gene sequencing of respiratory tract specimens have characterized the polymicrobial nature of lower airway infections in CF, including the coexistence of classic CF pathogens with both aerobic and anaerobic bacteria in the lower airways that were previously considered oropharyngeal contaminants. [156] [157] [158] [159] In a recent study of 269 children and adults with CF, 16S rRNA sequencing was used to investigate the lower airway microbiota. Despite significant interindividual variability in community structure and composition, the core microbiota included Streptococcus, Prevotella, Rothia, Veillonella, and Actinomyces. However, when classic CF pathogens such as Pseudomonas, Burkholderia, Stenotrophomonas, or Achromobacter were found to be present, they tended to dominate the microbial community within individuals. 156 Zemanick et al also corroborated these main findings, with classic CF pathogens found more commonly in adults. 111 Both Coburn et al and Zhao et al have described a decrease in both microbial diversity and lung function as age increases and lung disease progresses. 156, 160 Overall, these findings suggest that the microbiome of CF airways changes across ages and disease stages. In addition, recent studies based on 16S rRNA sequencing have highlighted the potential significance of anaerobes, whereby the relative abundance of anaerobic taxa in respiratory tract specimens of individuals with CF was dominant during pulmonary exacerbations. 161, 162 In summary, many studies of the CF microbiome have recently documented a diversity much more complex than that described by conventional culture alone, with changes in relative abundance and structure of microbial communities in response to age, disease progression, and acute clinical events. Further studies are needed to understand how these changes impact clinical outcomes and are affected by therapeutic interventions.

Infections of the lower respiratory tract remain a significant contributor to CF morbidity and mortality, even in the era of treatment that corrects and/or potentiates CFTR channel function. 163 Pathogens such as MRSA, P. aeruginosa, and species of the Bcc continue to have significant clinical impacts on lung function and mortality rates in individuals with CF. Advances in molecular technology will help our understanding of the microbial communities and their interactions in the CF airways. Due to the ongoing impact of pulmonary infections on CF patient survival, novel eradication strategies and effective chronic suppressive treatments are needed. 

replace Burkholderia multivorans

The emergence of a highly transmissible lineage of cblþ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain

The role of mucoidy in virulence of bacteria from the Burkholderia cepacia complex: a systematic proteomic and transcriptomic analysis

The cep quorum-sensing system of Burkholderia cepacia H111 controls biofilm formation and swarming motility

A decade of Burkholderia cenocepacia virulence determinant research

The multifarious, multireplicon Burkholderia cepacia complex

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria

Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis

Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis

Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis

Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis

Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis

Widespread clone of Burkholderia cenocepacia in cystic fibrosis patients in the Czech Republic

Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping

Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis

Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing

Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection

Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years' experience

Cystic Fibrous Foundation

Society for Healthcare Epidemiology of America. Infection prevention and control guideline for cystic fibrosis: 2013 update

Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak

Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis

Impact of burkholderia infection on lung transplantation in cystic fibrosis

Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis

Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization

Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia

Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime

Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients

The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants

Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence

Stenotrophomonas maltophilia in cystic fibrosis patients

Cystic Fibrosis Foundation

Canadian Patient Data Registry Report

Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients

Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis

Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis

Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease

Microbiology of CF Airway Disease Blanchard, Waters 733 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited

Genetic adaptation of Achromobacter sp. during persistence in the lungs of cystic fibrosis patients

Uncovering differences in virulence markers associated with Achromobacter species of CF and non-CF origin

Effect of highdose antimicrobials on biofilm growth of Achromobacter species isolated from cystic fibrosis patients

Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump

A beta-lactamase-overproducing strain of Alcaligenes denitrificans subsp. xylosoxydans isolated from a case of meningitis

Identification and distribution of Achromobacter species in cystic fibrosis

Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance

Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients

Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center

Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction

Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone

Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients

Clinical outcomes associated with Achromobacter species infection in patients with cystic fibrosis

Manual of Clinical Microbiology

Virulence factors in anaerobic bacteria

Anaerobic bacteria infection in cystic fibrosis airway disease

Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis

Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis

Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients

Analysis of lung microbiota in bronchoalveolar lavage, protected brush and sputum samples from subjects with mild-to-moderate cystic fibrosis lung disease

Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling

Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis

The role of short-chain fatty acids, produced by anaerobic bacteria, in the cystic fibrosis airway

Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis

Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upperairway specimens can misrepresent lung microbiota

Concordance between upper and lower airway microbiota in infants with cystic fibrosis

Fermentation products in the cystic fibrosis airways induce aggregation and dormancy-associated expression profiles in a CF clinical isolate of Pseudomonas aeruginosa

Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota

Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations

Airway microbiota across age and disease spectrum in cystic fibrosis

Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study

Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis

Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability

Consolidation of molecular testing in clinical virology

Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis

Viral respiratory infections in cystic fibrosis

Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis

Effects of upper respiratory tract infections in patients with cystic fibrosis

Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis

Respiratory virus infections in cystic fibrosis

Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study

The role of respiratory viruses in cystic fibrosis

Association between respiratory and herpes viruses on pulmonary exacerbations in cystic fibrosis patients

Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients

Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis

The effect of respiratory viral infections on patients with cystic fibrosis

Interferon response of the cystic fibrosis bronchial epithelium to major and minor group rhinovirus infection

Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis

Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation

Respiratory syncytial virus infection

Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

Rhinovirus C and respiratory exacerbations in children with cystic fibrosis

Influenza-associated cystic fibrosis pulmonary exacerbations

Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark

Severe viral respiratory infections in infants with cystic fibrosis

Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity

Multiplex PCR reveals that viruses are more frequent than bacteria in children with cystic fibrosis

Global analysis of the fungal microbiome in cystic fibrosis patients reveals loss of function of the transcriptional repressor Nrg1 as a mechanism of pathogen adaptation

Performance of MALDI-TOF MS platforms for fungal identification

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis

Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference

The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis

Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study

Invasive aspergillosis in cystic fibrosis: a fatal case in an adolescent and review of the literature

Selective isolation of Pseudallescheria and Scedosporium species from respiratory tract specimens of cystic fibrosis patients

Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases

Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study

Isolation of Exophiala dermatitidis from pigmented sputum in a cystic fibrosis patient

Sputum Candida albicans presages FEV 1 decline and hospital-treated exacerbations in cystic fibrosis

Lung microbiota across age and disease stage in cystic fibrosis

Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients

Airway microbiota in bronchoalveolar lavage fluid from clinically well infants with cystic fibrosis

Three clinically distinct chronic pediatric airway infections share a common core microbiota

Decade-long bacterial community dynamics in cystic fibrosis airways

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis

Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections